Enliven Shares Jump 33% This Week on CML Drug’s 48% Response Rate, $400M Raise
ELVN•Shares of Enliven Therapeutics rose 12% on Friday and 33% this week on encouraging Phase 1 data for ELVN-001 in chronic myeloid leukemia, with 48% of patients achieving major molecular response and 30% deeper response at 80 mg. The company aligned with the FDA on its Phase 3 trial design and priced an upsized offering expected to raise $400 million.
1. Phase 1 Data Drives Shares Higher
Enliven Therapeutics shares rose 12% on Friday and 33% over the week after updated Phase 1 results for ELVN-001 showed that 48% of chronic myeloid leukemia patients on the 80 mg dose achieved major molecular responses and 30% reached deeper responses; 6% discontinued due to adverse events.
2. FDA Alignment for Late-Stage Trial
The company secured alignment with the FDA on key elements of its planned late-stage trial design for ELVN-001, positioning it to initiate the Phase 3 study in the second half of 2026.
3. Upsized Public Offering to Fund Programs
Enliven priced an upsized public offering expected to generate approximately $400 million in gross proceeds before fees, aiming to fund its ELVN-001 program and support broader development initiatives.
4. Analyst Ratings and Sentiment
All 10 analysts covering Enliven rate the stock a Buy, with a 12-month average price target of $60.11 implying roughly 49% upside, while retail sentiment on social platforms remains elevated.
